Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
50.90
+0.34 (0.67%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Sanofi Revenue
In the year 2024, Sanofi had annual revenue of 44.29B EUR with 7.73% growth. Sanofi had revenue of 11.42B in the quarter ending December 31, 2024.
Revenue (ttm)
44.29B EUR
Revenue Growth
+7.73%
P/S Ratio
2.75
Revenue / Employee
534,352 EUR
Employees
82,878
Market Cap
126.26B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SNY News
- 9 hours ago - Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition - Reuters
- 10 hours ago - Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria - GlobeNewsWire
- 3 days ago - Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD - GlobeNewsWire
- 9 days ago - Global pharma shares plunge as Trump doubles down on tariff threat - Reuters
- 9 days ago - Trump teases targeted tariffs on overseas drug manufacturers - Market Watch
- 10 days ago - Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis - GlobeNewsWire
- 15 days ago - Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday? - Benzinga
- 15 days ago - Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines - GlobeNewsWire